Clinical outcomes of stereotactic body radiotherapy for patients with stage i small-cell lung cancer: Analysis of a subset of the japanese radiological society multi-institutional SBRT study group database

Japanese Radiological Society Multi-Institutional SBRT Study Group (JRS-SBRTSG)

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Stereotactic body radiotherapy (SBRT) is widely used as a curative treatment option for stage I non-small-cell lung cancer, but for patients with stage I small-cell lung cancer, the role of stereotactic body radiotherapy is unclear. In this study, we retrospectively analyzed the outcomes of a subset of patients with stage I small-cell lung cancer treated with stereotactic body radiotherapy in the database of the Japanese Radiological Society-Multi-Institutional stereotactic body radiotherapy Study Group. The 43 patients treated with stereotactic body radiotherapy for stage I small-cell lung cancer between 2004 and 2012 at 11 Japanese institutions were studied: median age = 77 years; 32 (74%) males and 11 females; and 80% were medically inoperable. The clinical stage was IA in 31 and IB in 12. In all patients, the lung tumors were pathologically proven as small-cell lung cancer. A total dose of 48 to 60 Gy was administered in 4 to 8 fractions. The median biologically effective dose (α/β = 10 Gy) was 105.6 Gy. Chemotherapy and prophylactic cranial irradiation were administered in only 8 patients, respectively. The median follow-up time was 23.2 months. The 2-year overall survival, progression-free survival, and distant metastasis-free survival rates were 72.3%, 44.6%, and 47.2%, respectively. The 2-year local control was 80.2%. Regarding the patterns of failure, distant metastasis, lymph node metastasis, and local recurrence were observed in 47%, 28%, and 16% of patients, respectively. No ≥grade 3 stereotactic body radiotherapy-related toxicities were observed. Although stereotactic body radiotherapy was thus revealed to be effective for the local control of stage I small-cell lung cancer, the incidence of distant metastases was high. Further investigations of larger cohorts are needed, including analyses of the effects of combined chemotherapy.

Original languageEnglish
JournalTechnology in Cancer Research and Treatment
Volume17
DOIs
Publication statusPublished - Jan 2018

Fingerprint

Radiosurgery
Small Cell Lung Carcinoma
Databases
Neoplasm Metastasis
Cranial Irradiation
Drug Therapy
Non-Small Cell Lung Carcinoma
Disease-Free Survival
Survival Rate
Lymph Nodes
Recurrence
Lung
Survival
Incidence
Neoplasms

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

@article{2301bf91f56540ba9edef33dbb4fd70c,
title = "Clinical outcomes of stereotactic body radiotherapy for patients with stage i small-cell lung cancer: Analysis of a subset of the japanese radiological society multi-institutional SBRT study group database",
abstract = "Stereotactic body radiotherapy (SBRT) is widely used as a curative treatment option for stage I non-small-cell lung cancer, but for patients with stage I small-cell lung cancer, the role of stereotactic body radiotherapy is unclear. In this study, we retrospectively analyzed the outcomes of a subset of patients with stage I small-cell lung cancer treated with stereotactic body radiotherapy in the database of the Japanese Radiological Society-Multi-Institutional stereotactic body radiotherapy Study Group. The 43 patients treated with stereotactic body radiotherapy for stage I small-cell lung cancer between 2004 and 2012 at 11 Japanese institutions were studied: median age = 77 years; 32 (74{\%}) males and 11 females; and 80{\%} were medically inoperable. The clinical stage was IA in 31 and IB in 12. In all patients, the lung tumors were pathologically proven as small-cell lung cancer. A total dose of 48 to 60 Gy was administered in 4 to 8 fractions. The median biologically effective dose (α/β = 10 Gy) was 105.6 Gy. Chemotherapy and prophylactic cranial irradiation were administered in only 8 patients, respectively. The median follow-up time was 23.2 months. The 2-year overall survival, progression-free survival, and distant metastasis-free survival rates were 72.3{\%}, 44.6{\%}, and 47.2{\%}, respectively. The 2-year local control was 80.2{\%}. Regarding the patterns of failure, distant metastasis, lymph node metastasis, and local recurrence were observed in 47{\%}, 28{\%}, and 16{\%} of patients, respectively. No ≥grade 3 stereotactic body radiotherapy-related toxicities were observed. Although stereotactic body radiotherapy was thus revealed to be effective for the local control of stage I small-cell lung cancer, the incidence of distant metastases was high. Further investigations of larger cohorts are needed, including analyses of the effects of combined chemotherapy.",
author = "{Japanese Radiological Society Multi-Institutional SBRT Study Group (JRS-SBRTSG)} and Yoshiyuki Shioyama and Hiroshi Onishi and Kenji Takayama and Yukinori Matsuo and Atsuya Takeda and Hideomi Yamashita and Akifumi Miyakawa and Naoya Murakami and Masahiko Aoki and Haruo Matsushita and Yasuo Matsumoto and Yuta Shibamoto",
year = "2018",
month = "1",
doi = "10.1177/1533033818783904",
language = "English",
volume = "17",
journal = "Technology in Cancer Research and Treatment",
issn = "1533-0346",
publisher = "Adenine Press",

}

TY - JOUR

T1 - Clinical outcomes of stereotactic body radiotherapy for patients with stage i small-cell lung cancer

T2 - Analysis of a subset of the japanese radiological society multi-institutional SBRT study group database

AU - Japanese Radiological Society Multi-Institutional SBRT Study Group (JRS-SBRTSG)

AU - Shioyama, Yoshiyuki

AU - Onishi, Hiroshi

AU - Takayama, Kenji

AU - Matsuo, Yukinori

AU - Takeda, Atsuya

AU - Yamashita, Hideomi

AU - Miyakawa, Akifumi

AU - Murakami, Naoya

AU - Aoki, Masahiko

AU - Matsushita, Haruo

AU - Matsumoto, Yasuo

AU - Shibamoto, Yuta

PY - 2018/1

Y1 - 2018/1

N2 - Stereotactic body radiotherapy (SBRT) is widely used as a curative treatment option for stage I non-small-cell lung cancer, but for patients with stage I small-cell lung cancer, the role of stereotactic body radiotherapy is unclear. In this study, we retrospectively analyzed the outcomes of a subset of patients with stage I small-cell lung cancer treated with stereotactic body radiotherapy in the database of the Japanese Radiological Society-Multi-Institutional stereotactic body radiotherapy Study Group. The 43 patients treated with stereotactic body radiotherapy for stage I small-cell lung cancer between 2004 and 2012 at 11 Japanese institutions were studied: median age = 77 years; 32 (74%) males and 11 females; and 80% were medically inoperable. The clinical stage was IA in 31 and IB in 12. In all patients, the lung tumors were pathologically proven as small-cell lung cancer. A total dose of 48 to 60 Gy was administered in 4 to 8 fractions. The median biologically effective dose (α/β = 10 Gy) was 105.6 Gy. Chemotherapy and prophylactic cranial irradiation were administered in only 8 patients, respectively. The median follow-up time was 23.2 months. The 2-year overall survival, progression-free survival, and distant metastasis-free survival rates were 72.3%, 44.6%, and 47.2%, respectively. The 2-year local control was 80.2%. Regarding the patterns of failure, distant metastasis, lymph node metastasis, and local recurrence were observed in 47%, 28%, and 16% of patients, respectively. No ≥grade 3 stereotactic body radiotherapy-related toxicities were observed. Although stereotactic body radiotherapy was thus revealed to be effective for the local control of stage I small-cell lung cancer, the incidence of distant metastases was high. Further investigations of larger cohorts are needed, including analyses of the effects of combined chemotherapy.

AB - Stereotactic body radiotherapy (SBRT) is widely used as a curative treatment option for stage I non-small-cell lung cancer, but for patients with stage I small-cell lung cancer, the role of stereotactic body radiotherapy is unclear. In this study, we retrospectively analyzed the outcomes of a subset of patients with stage I small-cell lung cancer treated with stereotactic body radiotherapy in the database of the Japanese Radiological Society-Multi-Institutional stereotactic body radiotherapy Study Group. The 43 patients treated with stereotactic body radiotherapy for stage I small-cell lung cancer between 2004 and 2012 at 11 Japanese institutions were studied: median age = 77 years; 32 (74%) males and 11 females; and 80% were medically inoperable. The clinical stage was IA in 31 and IB in 12. In all patients, the lung tumors were pathologically proven as small-cell lung cancer. A total dose of 48 to 60 Gy was administered in 4 to 8 fractions. The median biologically effective dose (α/β = 10 Gy) was 105.6 Gy. Chemotherapy and prophylactic cranial irradiation were administered in only 8 patients, respectively. The median follow-up time was 23.2 months. The 2-year overall survival, progression-free survival, and distant metastasis-free survival rates were 72.3%, 44.6%, and 47.2%, respectively. The 2-year local control was 80.2%. Regarding the patterns of failure, distant metastasis, lymph node metastasis, and local recurrence were observed in 47%, 28%, and 16% of patients, respectively. No ≥grade 3 stereotactic body radiotherapy-related toxicities were observed. Although stereotactic body radiotherapy was thus revealed to be effective for the local control of stage I small-cell lung cancer, the incidence of distant metastases was high. Further investigations of larger cohorts are needed, including analyses of the effects of combined chemotherapy.

UR - http://www.scopus.com/inward/record.url?scp=85055910482&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055910482&partnerID=8YFLogxK

U2 - 10.1177/1533033818783904

DO - 10.1177/1533033818783904

M3 - Article

C2 - 29983096

AN - SCOPUS:85055910482

VL - 17

JO - Technology in Cancer Research and Treatment

JF - Technology in Cancer Research and Treatment

SN - 1533-0346

ER -